

## PRIOR AUTHORIZATION REQUEST FORM EOC ID: Syprine (trientene)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (i	f applicable):
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or informat following	ion for this patient that may questions and sign.	support approval. Please answer the
Q1. Please provide ICD code(s) for diagnosis		
Q2. What diagnosis is this drug being prescribed for?		
☐ Wilson's disease	Other	
Q3. Is Syprine being used for acute copper toxicity or	removal?	
Yes	□No	
Q4. Is Syprine being used for maintenance therapy?		
Yes	□No	
Q5. If used for maintenance, does the patient have failu contraindication to zinc acetate?	re of an adequate trial of,	clinically significant intolerance, or
Yes	□No	
Q6. Does the patient have failure of an adequate trial of penicillamine (i.e. Depen Titratabs)?	f, clinically significant intole	erance, or contraindication to
Yes	□No	



## PRIOR AUTHORIZATION REQUEST FORM EOC ID: Syprine (trientene)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

Patient Name:	Prescriber Name:	
	Supervising Physician:	
Q7. Additional Comments		
Prescriber Signature	Date	
seriously jeopardize the life or health of the enrollee or the e  Lack of the necessary documentation may result in a medical nece	re, I certify that applying the standard review timeframe may nrollee's ability to regain maximum function ssity denial. Requesting providers may speak to a SWHP pharmacist in opportunity to help impact the decision on a request before coverage	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document